New immune cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT06307054
Summary
This early-stage trial is testing the safety and initial effectiveness of a new cell therapy called CLL-1 CAR-NK for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The study will give the modified immune cells to about 24 participants to find a safe dose and see how their bodies handle the treatment. The main goals are to check for serious side effects and see if the therapy can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.